• Ricardo Alonso Castillejos-Molina, Francisco Rodríguez-Covarrubias, Mariano Sotomayor de Zavaleta, Norma Uribe-Uribe, Leonardo Saúl Lino, and Guillermo Feria-Bernal.
• Departamento de Urologia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, DF México. rcastillejos@hotmail.com
• Rev Invest Clin. 2008 Sep 1; 60 (5): 360-4.

ObjectiveTo assess the outcome of patients with clinically localized prostate cancer (PCa) and seminal vesicle invasion (SVI) in the radical prostatectomy (RP) specimen.Material And Methods212 patients with clinically localized PCa underwent RP at our institution from 1988 to 2007. SVI (stage pT3bNOMO of the TNM 2002 system) was demonstrated in 40 (18.9%).ResultsPatients with SVI and PSA <10 ng/mL had better prognosis than those with a PSA > or =10 ng/mL, with a 5-year biochemical progression-free survival (bPFS) of 68.2% and 19.9%, respectively (p=0.008). In univariate analysis, an initial prostate specific antigen (PSA) > or =10 ng/mL (p=0.01) and preoperative high risk group (p=0.05) were related to the likelihood of biochemical failure. In multivariate analysis, only PSA remained independently associated to the risk of biochemical recurrence.ConclusionsIn the present study, the frequency of SVI was 18.9%. SVI confers a poor prognosis. Preoperative PSA > or =10 ng/mL was associated to the risk of biochemical recurrence.

23 keywords...

hide…